New agents in acute myeloid leukemia and other myeloid disorders (Q35639964)

9 August 2017

1 reference

title

New agents in acute myeloid leukemia and other myeloid disorders (English)

1 reference

9 August 2017

1 reference

acute myeloid leukemia

1 reference

Hagop Kantarjian

1 reference

9 August 2017

Jorge Cortes

1 reference

9 August 2017

Farhad Ravandi

1 reference

9 August 2017

Francis Giles

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

9 August 2017

1 reference

9 August 2017

volume

100

1 reference

9 August 2017

1 reference

9 August 2017

page(s)

441-454

1 reference

Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

Multidrug resistance in haematological malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

New designs for phase 2 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Nucleoside analogues: mechanisms of drug resistance and reversal strategies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Methylation profiling in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Hypermethylation of GpG islands in the promoter region of p15(INK4b) in acute promyelocytic leukemia represses p15(INK4b) expression and correlates with poor prognosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Lentivirus administration to rat muscle provides efficient sustained expression of erythropoietin.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Oncogenic kinase signalling

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Novel mechanisms of RTK signal generation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Switching signals on or off by receptor dimerization

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

The roles of FLT3 in hematopoiesis and leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Role of FLT3 in leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Blocking oncogenic Ras signaling for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Induced disruption of the transforming growth factor beta type II receptor gene in mice causes a lethal inflammatory disorder that is transplantable

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Dysregulation of apoptosis in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Apoptosis and cancer drug targeting

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Destabilizing influences in apoptosis: sowing the seeds of IAP destruction

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

The inhibitors of apoptosis (IAPs) and their emerging role in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

The proteasome: a novel target for cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

How proteolysis drives the cell cycle

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Development of anticancer drugs targeting the MAP kinase pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

A mammalian protein targeted by G1-arresting rapamycin-receptor complex

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Targeting mTOR signaling for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.11935

1 reference

7 January 2021

Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinosi

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Tumor therapy with targeted atomic nanogenerators

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Novel agents for the therapy of acute leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Role of co-repressors in transcriptional repression mediated by the t(8;21), t(16;21), t(12;21), and inv(16) fusion proteins

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Low NAD(P)H:quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11935

7 January 2021

Identifiers

DOI

10.1002/CNCR.11935

1 reference

9 August 2017

1 reference